This paper follows up a previous paper reported in this journal. This study was a single-blind parallel comparison of naproxen sodium ("Synflex") and a paracetamol/dextropropoxyphene combination ("Distalgesic"). It was carried out in 184 patients suffering from soft-tissue disorders recruited from four centres.
INTRODUCTION
Soft-tissue disorders have been previously treated with rest, elevation, support and immobilisation, with analgesics being prescribed to provide pain relief. Current *presentWAddress: thinking suggests that prostaglandins may be implicated RAF Brawdy, W. Wales in the inflammatory process associated with these injuries and that an analgesic drug which also inhibits **Present Address: prostaglandin production may be of benefit (Muckle, Royal Military Academy, Sandhurst, Surrey 1980).
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Naproxen is a non-steroidal anti-inflammatory agent which has potent analgesic, anti-pyretic and anti-inflammatory properties (Roszkowski et al, 1971) . When administered as the sodium salt it is quickly absorbed and produces rapid pain relief (Filtzer, 1980; Sevelius et al, 1980a; Sevelius et al, 1980b) . Consequently this study was set up to establish the comparative efficacy and side-effect profile of naproxen sodium and a widely used analgesic combination, paracetamol/dextropropoxyphene, in soft-tissue injuries. A preliminary communication on this study (Abbott et al, 1980 ) reported a 'better clinical response with naproxen sodium than with the analgesic combination in 98 patients. The completed study on 184 patients is now reported.
PATIENTS AND METHODS
One hundred and eighty-four patients from four centres were entered into a single-blind parallel comparison of naproxen sodium* and a combination of paracetamol and dextropropoxyphene**. Ethical committee approval and patients' informed consent were obtained.
Patients admitted to the study were those who had recently suffered acute musculo-skeletal disorders or acute traumatic sports injuries. Ninety-eight patients were armed forces personnel and 86 patients were recruited from general practice.
Patients were allocated randomly to one of two treatment groups, either to naproxen sodium capsules ("NS group") 275 mg (one capsule three times daily) or to tablets containing 325 mg paracetamol and 32.5 mg dextropropoxyphene ("control group") (2 tablets three times daily). Treatment was for seven or 14 days depending on the patients' condition at the seven-day assessment.
The mean age of the 93 patients (72 males and 21 females) in the NS group was 32.6 years, and in the control group the mean age of the 91 patients (70 males and 21 females) was 34.0 years. The two groups were found to be matched on admission for age, sex, injury severity, pain, tenderness, swelling and limitation of movement (see Table 1 ).
The majority of patients (78%) were seen within a week of the injury occurring, the major diagnosis being muscle injury (29% of the injuries).
Severity of injury, pain, tenderness, swelling and ability to move the affected part were assessed on admission (Table I ) and after seven and 14 days of treatment. A total symptom score was obtained by addition of each patient's score for severity of pain, tenderness, swelling and ability to move the affected part (limitation of movement).
Side-effects were elicited by indirect questions such as "How is the treatment suiting you?"
Patients were also asked to keep daily record cards assessing pain, ability to move the affected part and kBLE I Admission symptoms -number of patients Table 11 shows the mean scores of pain, tenderness, swelling, limitation of movement and the total symptoms score on admission, at the day seven assessment, and at the day 14 assessment. As shown in Table II naproxen sodium was significantly better than the paracetamol/dextropropoxyphene combination in terms of pain at the day seven assessment. For those patients who carried on for 14 days treatment, the total symptom score was significantly different in favour of naproxen. There were no significant differences between the two treatment groups at the day 7 and the day 14 follow-up for scores of tenderness, swelling and limitation of movement. At day seven all parameters had improved significantly from baseline, for both groups. Table Ill shows the number of patients judged to be cured, improved, the same or worse at the day seven and day 14 follow-up visits.
RESULTS

Clinical Assessment
By day seven 92% of the patients assessed in the NS group were judged to be cured or improved, whilst in the control group 80% of the patients assessed were cured or improved by day seven.
Patients Daily Record
Both treatment groups showed significant improvement over baseline in pain and limitation of movement each day. There were no significant differences between treatments. Patients' daily records of change since the previous day showed the NS group to be improved more significantly than the paracetamol/dextropropoxyphene combination by day two (Mann-Whitney p < 0.002) (Fig. 1) .
Withdrawals from the Study and Side-Effects A total of ten patients withdrew from the study. Two patients in the NS group withdrew from the study due to lack of efficacy and switched to other medication. Eight patients withdrew from the trial due to sideeffects. Two of these were from the NS group, one because of nausea, and the other because of visual upset, lightheadedness and drowsiness. The six patients from the control group withdrew due to the following side-effects: (1) nausea and vertigo; (2) (Crean, 1981) that pain or fear of pain is the biggest single factor in delaying full rehabilitation. Previous work has shown that analgesic anti-inflammatory drugs such as ibuprofen (Blonstein, 1974; Muckle, 1974) , indomethacin (Buelvas, 1967; Leclerc and Autissier, 1969; Huskisson et al, 1973) and naproxen sodium (Wheatley, 1979) are of benefit in these conditions. Studies of naproxen sodium against indomethacin (Backhouse e~t al, 1980) and against ibuprofen (Bodiwala, 1981) have shown naproxen sodium to be similar to or better than the comparative agents in relieving symptoms and side-effects to be fewer in the naproxen sodium group.
This study extends the previous report comparing naproxen-sodium and a paracetamol/dextropropoxyphene combination (Abbott et al, 1980) . The previous findings that the symptom scores in the naproxen sodium group tended to be lower than in the analgesiccombination group after seven days of treatment are confirmed. The NS group had a significantly lower pain score in this larger sample of patients. For the patients who required a further seven days treatment, the trend was again in favour of the NS group. The total symptom score in the naproxen sodium group was significantly lower than in the analgesic combination group.
Side-effects were fewer in the naproxen sodium group, and more patients stopped treatment due to sideeffects in the analgesic-combination group.
An analgesic, anti-inflammatory agent such as naproxen sodium would appear to be useful in the treatment of non-articular soft-tissue injuries by producing fast pain relief with minimal side-effects.
